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STUDY PROTOCOL Open Access
The VOICE Study: Valuing Opinions,
Individual Communication and Experience:
building the evidence base for undertaking
Patient-Centred Family Meetings in
palliative care - a mixed methods study
Philippa J. Cahill1,5*, Christine R. Sanderson1,4, Elizabeth A. Lobb1,4 and Jane L. Phillips2,3
Abstract
Background: Despite family meetings being widely used to facilitate discussion among patients, families, and clinicians
in palliative care, there is limited evidence to support their use. This study aims to assess the acceptability and feasibility of
Patient-Centred Family Meetings in specialist inpatient palliative care units for patients, families, and clinicians and
determine the suitability and feasibility of validated outcome measures from the patient and family perspectives.
Methods: The study is a mixed-methods quasi-experimental design with pre-planned Patient-Centred Family Meetings
at the intervention site. The patient will set the meeting agenda a priori allowing an opportunity for their issues to be
prioritised and addressed. At the control site, usual care will be maintained which may include a family meeting. Each
site will recruit 20 dyads comprising a terminally ill inpatient and their nominated family member. Pre- and post-test
administration of the Distress Thermometer, QUAL-EC, QUAL-E, and Patient Health Questionnaire-4 will assess patient
and family distress and satisfaction with quality of life. Patient, family, and clinician interviews post-meeting will provide
insights into the meeting feasibility and outcome measures. Recruitment percentages and outcome measure
completion will also inform feasibility.
Descriptive statistics will summarise pre- and post-meeting data generated by the outcome measures. SPSS will analyse
the quantitative data. Grounded theory will guide the qualitative data analysis.
Discussion: This study will determine whether planned Patient-Centred Family Meetings are feasible and acceptable and
assess the suitability and feasibility of the outcome measures. It will inform a future phase III randomised controlled trial.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12616001083482 on 11 August 2016
Keywords: Palliative care, Family, Meeting, Conference, Terminal care
Background
Effective communication in palliative care practice is central
to adequately addressing patient and family needs and con-
cerns [1–3]. The bringing together of patients, family, and
clinicians for a purposeful discussion has been recognised as
a means of assisting with patient-family and clinical team
communication in the specialist palliative care setting [4–7].
This “family meeting” or “family conference,” as it is vari-
ously referred to in the literature [5, 6], facilitates discussion
about the illness experience, care choices, and end-of-life
decision-making [5, 8, 9]. In this setting, “family” is defined
as whomever the patient designates as “family” and may
include close friends or carers [10].
Only a limited number of studies have been undertaken
to examine the outcomes of family meetings. Hannon et al.
[11] demonstrated that unmet family needs and concerns
were significantly improved as a result of family meetings.
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The authors recommended further studies to review the
impact of family meetings from the family and clinician
perspective and to incorporate qualitative data collection.
A prospective study [12] of family meetings demonstrated
that the high levels of verbal expression of distress exhibited
by primary caregivers were not significantly affected by the
presence of the patient. However, other family members
verbally expressed their emotional distress more often
when the patient was absent. Patient presence was also sig-
nificantly associated with increased discussion regarding
goals of care and decreased discussion about prognosis and
the symptoms dying patients may experience [12]. In this
study, no validated measures were used to assess distress,
and patients did not routinely participate in the family
meetings. The authors of the study [12] recommended
identification of patient preferences for family meeting
structure and procedures, and that consideration should be
given to a randomised control trial (RCT) to compare
patient and family participation with family only participa-
tion in family meetings.
Guidelines for Conducting Family Meetings in Palliative
Care were developed in Australia [6], and provide a struc-
tured approach for preparing and conducting a family
meeting. An evaluation of the Guidelines’ effectiveness
[13] and their impact on family outcomes demonstrated a
significant increase post-meeting in the overall means for
addressing important family needs [13]. The timing of the
family meeting and a review of patient benefits were sug-
gested as important areas for further research [13]. The
authors concluded that family meetings were acceptable
and feasible to ascertain and deal with family concerns;
however, the authors did not document the feasibility and
acceptability for patients and clinicians.
A recent systematic review [14] examined what measure-
able health outcomes improved as a result of family meet-
ings convened in acute and sub-acute inpatient care
settings, including palliative care [14]. This review found
low-to-moderate positive evidence that family meetings led
to a reduction in family psychological distress and ad-
dressed the information and support needs of families [14].
Further research to assess patient outcomes and the pa-
tient’s role in family meetings was recommended. A more
recent review found a dearth of evidence to support the use
of family meetings in palliative care [15]. In particular, there
was no study that demonstrated patient benefits using a
validated measure and only two studies used a validated
measure to demonstrate family benefits as a result of par-
ticipation in a family meeting. There was also limited quali-
tative evidence to support positive outcomes for patients,
families and clinicians participating in a family meeting.
Overall there is limited high-level evidence to demon-
strate the benefits of family meetings for patients, families
and clinicians in the palliative care context. The feasibility
and acceptability of family meetings has only been
confirmed for families [13]. The authors of published
studies have recommended that additional research is re-
quired to assess patient outcomes, preferences, and par-
ticipation in family meetings in the palliative care setting
[12, 13] and that clinician outcomes should also be evalu-
ated [11]. The use of qualitative data [11], to assess the im-
pact of family meetings on family participants and to
examine the timing of family meetings [13] have also been
advocated as areas for further investigation. In addition,
the majority of studies have not used validated measures
to evaluate the impact of family meetings on participants,
in particular patient and family distress [12, 14, 16].
Therefore, there is a clear need to undertake research using
quantitative and qualitative data to assess the feasibility,
acceptability and impact of family meetings from the per-
spective of all participants - patient, family and clinicians. A
clearer understanding of the patient’s role and their prefer-
ences for family meetings is imperative given: (a) the vulner-
ability of this patient cohort; (b) the uncertainty regarding
the value of family meetings in palliative care; (c) the
resource intensity of clinician time associated with this inter-
vention [11]; and (d) the current intuitive belief that these
meetings are an important aspect of standard care [8, 17].
In the proposed study, qualitative data collection with in-
terviews of patients, families and clinician focus groups will
assess the feasibility and acceptability of Patient-Centred
Family Meetings and the suitability and feasibility of the
measures used. Patients will complete the QUAL-EC
questionnaire [18] and family members will complete the
corresponding QUAL-E (Family) questionnaire [19] to
measure patient and family satisfaction with quality of life
at end-of-life. Patients and families will complete the
National Cancer Collaborative Network (NCCN) Distress
Thermometer [20] as a measure of distress and families will
complete the PHQ-4 (Patient Health Questionnaire-4)
[21–23] as an additional distress measure.
As recruitment will be from a palliative care population,
patients who are terminally ill or debilitated can affect
data collection. This issue will be addressed by the eligibil-
ity criteria. The Palliative Care Outcomes Collaboration
(PCOC) palliative care phase classification system [24] will
be used to confirm that the patient is not in the terminal
phase and the Australian Modified Karnofsky Perform-
ance Score [25] will be used to confirm the physical cap-
ability of the patient to participate in the VOICE Study.
Objectives
The primary objectives of the VOICE Study are to:
(i) Assess the acceptability and feasibility of providing
planned Patient-Centred Family Meetings in a
specialist inpatient palliative care unit for patients,
families and clinicians;
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(ii)Understand the benefits and burden of participating
in a Patient-Centred Family Meetings from the
patient, family and clinician perspective; and
(iii)Assess the suitability and feasibility of the selected
outcome measures for patients and families.
The secondary objective is to inform the development
of a future phase III RCT.
The principles of patient-centred care [26] will underpin
the proposed intervention and are congruent with the
clinical practice of palliative care [27]. For this reason, the
family meeting intervention in this study will be referred
to as a Patient-Centred Family Meeting. The recognition
of the patient as an individual and the obligation to ac-
knowledge their unique needs, wants, values and concerns
and those of their family and/or significant others (if
present) is paramount. The Patient-Centred Family Meet-
ing will focus on the patient and give them a “voice” by fa-
cilitating the meeting discussion concerning their needs,
concerns opinions and experiences. The VOICE acronym
reflects this concept. By also assessing the acceptability
and feasibility of Patient-Centred Family Meetings from
the perspective of families and clinicians, all participants
are given a “voice” in the VOICE Study.
Research design
The VOICE Study Research Protocol (Version 5.6,
11.3.2017) will utilise a mixed methods quasi-experimental
(pre-post-test) design. The specific strategy used to mitigate
factors that may compromise internal validity will be a
non-equivalent control group design. This design incorpo-
rates a comparison (control) group and collection of
equivalent pre-test and post-test measures for the interven-
tion and comparison (control) groups [28]. The SPIRIT
checklist [29] was used to inform the study protocol and is
included as an additional file.
Methods/Design
Study setting
Two sub-acute facilities in Sydney, Australia who pro-
vide specialist inpatient and community palliative care to
the local geographic population will be included in the
VOICE Study with one being a control site and the
other the intervention site. The study design will incorp-
orate four study groups:
(i) Inpatients receiving the intervention of a planned
Patient-Centred Family Meeting;
(ii)Family member(s) (or equivalent person) who
are invited by the patient to participate in a
Patient-Centred Family Meeting;
(iii)Inpatients receiving standard care (who may also
participate in a “standard” family meeting);
(iv)Family member(s) (or equivalent person) nominated
by the patient to participate in the VOICE Study.
The control site will provide their usual palliative care,
which may or may not include a family meeting. This con-
trol site will provide insights into standard palliative care
practices, such as how the team determines who needs a
family meeting. The intervention site will provide a planned
Patient-Centred Family Meeting for patients and families.
The same outcome measures will be collected at each site
to help identify factors or confounding variables that oper-
ate in standard palliative care practice that may not be
apparent at the intervention site. For the purposes of this
research study, “family” is defined as whomever the patient
designates as “family” and may include close friends or
carers or significant others [10].
At each facility, the Director of the Palliative Care
Service will act as the on-site Principal Investigator and
will liaise with the on-site palliative care clinical staff
and the PhD student (corresponding author). The other
authors will be supervising the PhD student for the
VOICE Study and will be involved in decisions concern-
ing data management and publications and consultation
with the on-site principal investigators as required.
Participant eligibility criteria
Inclusion criteria
Patients All patients (aged ≥ 18 years) admitted to a spe-
cialist palliative care unit within the last 7 days with a
terminal illness (a prognosis of ≤ 12 months, but expected
to live at least 14 days, i.e., the average length of the proto-
col) will be included. The patient must be able to identify
a primary support person who agrees to participate in the
Patient-Centred Family Meeting (intervention arm) or the
control arm of the study. In order to be well enough to
participate in a Patient-Centred Family Meeting, the pa-
tient will have a Australian Modified Karnofsky Perform-
ance Score ≥ 30 [25]. The patient must also be classified
at recruitment as being either “Stable”, “Unstable,” or
“Deteriorating” in accordance with Palliative Care Out-
comes Collaboration (PCOC) palliative care phase classifi-
cation system [24].
Family Participating family members must be aged ≥
18 years.
All patient and family participants will have sufficient
English language and cognitive skills to complete an in-
formed consent, complete baseline information and ques-
tionnaires and contribute effectively in the Patient-
Centred Family Meeting or family meeting if it occurs as
part of usual care. The researchers recognise the import-
ance of non-English speaking patients and families in the
provision of quality palliative care and providing them with
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the opportunity to participate in research studies. However,
the validated palliative care measures which will be used in
this study have not been validated for patients with insuffi-
cient English literacy to complete the questionnaires [18].
Exclusion criteria
Patients who are receiving treatment for curative intent, who
are in the “Terminal” phase as measured by PCOC assess-
ment [24] or who are cognitively impaired, will be excluded.
Family members who have not been invited to attend
the Patient-Centred Family Meeting (intervention) by a
participating patient will be excluded.
Intervention
The intervention is a planned face-to-face Patient-Centred
Family Meeting for the inpatient and family member(s)
after inpatient admission to a specialist palliative care
facility that is the designated intervention site. The dur-
ation of the Meeting will be 60 min, although this may
vary depending on patient and family members’ needs.
The intervention is designed to be “patient-centred” with
the patient setting the agenda in advance so that their
concerns and issues are addressed. The baseline informa-
tion about the patient's issues, concerns and expectations
of their inpatient stay will inform the Patient-Centred
Family Meeting agenda. Meeting discussion may include
clinical and psycho-social issues, preparation for death
and other key areas of importance for that patient and
family. The Meeting will be scheduled as soon as practic-
able after the patient’s admission and be conducted in a
private space with members of the palliative care multidis-
ciplinary team. Routinely, the palliative care consultant
and/or registrar and social worker will attend. Other
members of the team will participate as required or as re-
quested by the patient during preparation for the meeting.
A participant attendance sheet will be completed.
The palliative care consultant or social worker will facili-
tate the meeting, according to the Manual for Patient-
Centred Family Meetings. The researcher will provide edu-
cation to the clinical staff prior to commencement of the
study and will attend Patient-Centred Family Meetings to
observe for fidelity to the Manual procedures.
Other than the Patient-Centred Family Meeting, all
other usual palliative care practices will be provided to the
patient and their family.
Control
The Patient-Centred Family Meeting will not be offered
at the control site. Usual care will be maintained which
may include a family meeting that is held as part of the
facility’s usual care. The need for a family meeting will
be determined as per the facility’s usual clinical practice.
A proportion of these “standard” family meetings will be
observed using the family meeting observation sheet.
For both the intervention and control sites, if, following
consent, the patient’s mental state changes, the researcher
or clinical trials nurse will consult the clinical team con-
cerning the appropriateness of the patient continuing in
the study. The clinical team will be asked to consider the
patient’s mental state to assess if the patient fulfils the
exclusion criteria of cognitive impairment. If the patient
does fulfil the exclusion criteria, the patient will be with-
drawn from the study. The family member(s) participating
in the study will be informed and the family member will
also be withdrawn from the study.
Outcomes
Both qualitative and quantitative data and will be collected
for the VOICE Study. Qualitative data will assess the pri-
mary outcome of the VOICE Study to determine the feasi-
bility and acceptability of a Patient-Centred Family
Meeting in specialist palliative care units for all partici-
pants. This data will also contribute to understanding the
benefits and burden of participating in a Patient-Centred
Family Meeting from the perspective of all participants.
Qualitative and quantitative data will also be used to de-
termine the secondary outcome of the VOICE Study con-
cerning the suitability and feasibility of the proposed
outcome measures for patients and families.
Qualitative data
At the intervention site, a Patient-Centred Family Meeting
patient semi-structured interview schedule will be under-
taken with participating patients 1–2 days post-meeting
that includes questions related to the feasibility and
acceptability of the Patient-Centred Family Meeting such
as: “What was the family meeting like for you?” This inter-
view will also be undertaken at the control site using the
same interview schedule if the patient participates in a
family meeting as part of standard care. At both sites,
patients will be asked about the measures used to assess
their suitability and feasibility.
At the intervention site, the family participant will
complete a Patient-Centred Family Meeting feedback
questionnaire post meeting. At the control site, a family
meeting feedback questionnaire will be completed post
meeting if a family participates in a family meeting as part
of standard care. Both feedback questionnaires will
include questions about the family’s experience of the
positive and negative aspects of the meeting attended.
Family semi-structured interviews will also be undertaken
at both sites to discuss questions related the feasibility and
acceptability of the Patient-Centred Family Meeting or
"standard" family meeting for example “Do you think the
family meeting was helpful or not helpful for the family
members who attended?” and to also assess the suitability
and feasibility of the measures used. All interviews will fol-
low a semi-structured schedule to ensure consistency.
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At the intervention site, the Patient-Centred Family
Meeting multidisciplinary staff focus group semi-structured
interview schedule will be used to evaluate the feasibility
and acceptability of clinicians participating in Patient-
Centred Family Meetings. Focus groups will use a moder-
ator and an observer to ensure consistency across each
focus group and keep the participants on track. Questions
such as “Do you think it is feasible to provide these meet-
ings as part of standard care?” will be asked. The clinician
focus groups will include members of the multidisciplinary
specialist palliative care team e.g. medical, nursing and
allied health clinicians who have been involved in the care
of patients and their families, and participated in at least
one patient-centred family meeting. The purpose of these
focus groups is to (a) explore the clinicians’ experience of
the Patient-Centred Family Meetings process; (b) identify
positive and less positive aspects; and (c) assess the accept-
ability and feasibility of the model such as the time involved
and the benefits. The clinician focus groups provide a
“voice” for the multidisciplinary team members and echo
the VOICE Study acronym.
A family meeting observation sheet will record key ele-
ments of the Patient-Centred Family Meeting during the
meeting. The data will include who attended the meeting,
reasons for participants’ non-attendance and record which
components of the pre-set patient agenda were discussed.
Quantitative measures
Measures of patient and family satisfaction with quality of
life at end-of-life and patient and family distress will be col-
lected using validated measures, and these measures will
be evaluated qualitatively as described above, to assess
their suitability and feasibility for patients and families.
The QUAL-EC [18] questionnaire will assess the con-
sented patients’ symptom control, their relationship with
the healthcare provider, life completion, and preparation
for end-of-life. The QUAL-E (Family) [19] questionnaire
will measure the experience of consented family mem-
bers’ whose relatives are enrolled in the VOICE Study.
The questionnaire will assess the relationship with the
healthcare provider and the completion of the relation-
ship with the patient. The family will also report on the
patient’s symptom experience, preparation for death, and
state of peace.
The NCCN Distress Thermometer [20] will be used to
assess changes in distress of patients and family members
pre- and post-patient-centred family meetings. The PHQ-
4 [21–23] combines the Patient Health Questionnaire-2
and Generalised Anxiety Disorder (GAD)-2, and will be
used as an additional distress measure for families.
A single question measure: “To what extent are you at
peace?” will explore the patients’ spiritual and emotional
well-being [30].
The use of the QUAL-EC as a patient outcome measure
is based on the rationale that the quality of life at the end
of life measures and domains assessed may be impacted
by participation in the Patient-Centred Family Meeting.
The rationale for the use of the QUAL-E (Family) tool was
based on it being the companion instrument for the
QUAL-EC and that it will also measure domains of the
family experience that may be affected by participation in
a Patient-Centred Family Meeting.
The NCCN Distress Thermometer instrument has
been used previously to assess changes in distress of key
family members pre- and post-family meetings [31]. The
VOICE Study will provide an opportunity to assess the
feasibility and suitability of the PHQ-4 tool in the con-
text of palliative care and is not likely to be burdensome
for the family member. However as it was considered an
additional burden for the patient it will not be used. In
the event that the scores obtained on either the NCCN
Distress Thermometer or PHQ-4 indicate significant
distress, the clinical team will be informed.
The peace question will be used in the VOICE Study
as an additional patient measure to assess any differ-
ences in the patients’ perception of peace pre and post
participation in the Patient-Centred Family Meeting.
Sample size
Twenty inpatients will be recruited from each facility. At
each site, the patient will nominate one family member
(or equivalent) as the primary support person to partici-
pate in the study. A total of 20 patient-family dyads will
be recruited for each site, resulting in 40 participants at
each site and a total of 80 participants for the entire
study. The total number may exceed this if additional
family participants wish to attend the Patient-Centred
Family Meeting or standard care family meeting. Data
will be collected from additional family participants who
consent to study inclusion. A power calculation was not
undertaken as this will be a feasibility study.
Recruitment
The researcher at the intervention site and the clinical
trials nurses at the control site will review the clinical
record of newly admitted patients and undertake neces-
sary screening for eligibility, and if required, speak with
the clinical staff to clarify any aspects of inclusion
criteria such as cognitive status. This visit will not
directly involve the patient. During the course of the
study at the intervention site, the researcher will main-
tain a visible presence at the facility to ensure that all
eligible patients are identified and recruited in a timely
manner. The involvement of experienced clinical trials
nurses at the control site is expected to enhance partici-
pant recruitment to the study at this facility.
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Data collection methods for the intervention arm of the
study
The patient and family participant timeline and data
collection for both arms of the study are summarised in
Table 1, and a detailed description of these key tasks for
the intervention arm is outlined below.
Days 1–2 screening
Recruitment of patients and family members will com-
mence Days 1–2 following admission. The researcher will
review the clinical record of all newly admitted patients to
screen for eligibility according to the inclusion criteria for
the VOICE Study. Clinical staff will clarify any issues or
information concerning the patient’s status such as their
cognitive status or palliative care phase [24] .
Days 2–3 recruitment and consent
On Days 2–3 of admission, all eligible patients will receive
a formal written “Invitation to attend a Patient-Centred
Family Meeting” and if they are interested, the patient will
be given the Patient-Centred Family Meeting Introductory
Patient Information sheet. The study will be discussed with
the patient and issues addressed by the researcher. Inter-
ested patients will be provided with the Patient-Centred
Family Meeting Participant (patient) Information Statement
and Consent Form. Patients who agree to participate will
be asked to complete the consent form. If the patient
requires more time to consider participation, the researcher
will return at a later date to finalise recruitment.
Days 3–5 baseline data collection
Consented patients will then be asked to complete the
Patient-Centred Family Meeting Patient Information Book-
let that includes:
(i) baseline patient information, demographics and
questions that will guide the Patient-Centred Family
Meeting agenda,
(ii)the QUAL-EC questionnaire [18, 32]
(iii)the NCCN Distress Thermometer [20]
(iv) the single question measure: “To what extent are
you at peace?”.
Consented patients will be asked to nominate and pro-
vide contact details of the primary support person who
the patient would like to participate in the proposed
Patient-Centred Family Meeting. If required, the
researcher or social worker will assist with contacting
the support person and teleconferencing will be made
available if required. The patient may also nominate
additional family members or significant others to be
included in the study and/or attend the Patient-Centred
Family Meeting.
The nominated family member(s) will be contacted and
given a copy of the Patient-Centred Family Meeting intro-
ductory Family Information. The study will be explained to
the family member(s) and questions or issues discussed. A
Patient-Centred Family Meeting Participant (family) Infor-
mation Statement and Consent Form will be provided and
further questions addressed. Interested family member(s)
who are on site will be consented immediately or the con-
sent form will be completed prior to the Patient-Centred
Family Meeting commencing. The Patient-Centred Family
Meeting Family Information Booklet which includes ques-
tions about the patient and pre-meeting measures: QUAL-E
(Family) questionnaire; the NCCN Distress Thermometer;
and the PHQ-4 will be completed prior to the meeting.
If an invited family member(s) or significant other(s) do
not meet the criteria or will not consent, the patient will
nominate an alternative participant. If this is not possible,
the patient will be excluded.
Days 5–10 Patient-Centred Family Meeting and repeat
patient measures
The researcher or social worker will arrange the Patient-
Centred Family Meeting in consultation with the patient,
family, and clinicians between days 5–10. During the
Patient-Centred Family Meeting, the researcher will
complete the family meeting observation sheet. Within
24–48 h post-meeting, the researcher will interview the
patient using the Patient-Centred Family Meeting pa-
tient semi-structured interview schedule. The patient
will also complete repeat QUAL-EC and NCCN Distress
Thermometer measures.
Day 14 repeat family measures
On Day 14, family participant(s) will complete the
Patient-Centred Family Meeting family feedback ques-
tionnaire and repeat measures of the QUAL-E (Family),
NCCN Distress Thermometer and PHQ-4 by telephone
or on-site according to their availability. A sample of
family members (n = 10) will also participate in an inter-
view, using the QUAL-E (Family) questions as prompts
for further discussion about families’ views concerning
the relevance of the measures, time taken to complete,
any issues about the measures and their preference(s)
for a particular measure. This interview will be con-
ducted by telephone or face-to-face based on availability.
Data collection for the intervention arm of the study for
clinicians
After the completion of a number of Patient-Centred
Family Meetings, a focus group will be convened to seek
the views of multidisciplinary team members who have
cared for the patients recruited to the VOICE Study and
attended at least one Patient-Centred Family Meeting.
Additional focus groups will occur during the course of
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the VOICE Study to include additional team members
and ensure data saturation. However, each team member
will only be required to attend one focus group.
Data collection methods for the control arm of the
research study (Table 1)
Days 1–2 screening
A clinical trials nurse will undertake the same eligibility
screening procedures as undertaken at the intervention site.
Days 2–3 recruitment and consent
On Days 2–3 of admission, eligible patients will
receive the introductory patient information and the
study will be discussed with the patient and any ques-
tions or concerns addressed. Interested patients will
receive the Participant (patient) Information State-
ment and Consent Form and written consent will be
obtained. If the patient requires more time to con-
sider, the clinical trials nurse will return to finalise
recruitment.
Table 1 VOICE Study patient and family participant timeline for enrolment, interventions, and assessments at intervention and
control sites
STUDY PERIOD
Enrolment Allocation Post-allocation Close-Out
Time point
Site 
Day 1-2 Day 2-3 Day 3-5
IS, CS
Day 5-7
IS, CS
Day 7
CS
Day 7-
10
IS, CS
Day 10-
14
IS, CS
Day 14
IS, CS
ENROLMENT: Both 
sites
Eligibility screen X
Informed Consent X
Allocation (CS, IS) X
INTERVENTIONS:
Patient-Centred Family 
Meeting (IS)
Usual care (CS)
ASSESSMENTS:
Baseline patient 
QUAL-EC, NCCN DT, 
Peace Question  
Baseline family 
information, QUAL-E, 
NCCN DT, PHQ-4    
Family Meeting 
observation data (IS) 
Family Meeting 
observation if meeting 
held (CS)
Patient-centred Family 
Meeting Patient 
interview 
Family Meeting Patient 
interview 
QUAL-EC and NCCN 
DT (CS)
X
QUAL-EC and NCCN 
DT (IS)
Patient-Centred Family 
Meeting Family 
Feedback 
Questionnaire 
X
Family Meeting Family 
Feedback 
Questionnaire if 
meeting held 
X
QUAL-E (Family), 
NCCN DT, PHQ-4 
X
Family interviews X
Day 1 day of admission, CS control site, IS intervention site, NCCN DT National Cancer Collaborative Network Distress Thermometer, PHQ-4 Patient Health
Question Questionnaire-4
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Days 3–5 baseline data collection
The consented patient will complete the Patient Infor-
mation Booklet that includes information about family,
the QUAL-EC and the NCCN Distress Thermometer.
Consented patients will nominate a primary support per-
son to participate in the study. The patient may also
invite additional family members or significant others to
be included in the study and/or attend any family meet-
ing held. The nominated family member(s) will be given
study information and any questions or issues discussed.
Consented family member(s) will complete the Family
Information Booklet that includes patient-related ques-
tions and the outcome measures used at the intervention
site. If the family member is unavailable, the family
member will be requested to complete the consent form
and Family Information Booklet by Day 7 of the patient’s
admission. If the nominated family member(s) does not
meet the criteria or will not consent, the patient will
nominate an alternative person. If this is not possible,
the patient will be excluded.
Day 7 repeat patient measures
On Day 7, the patient will complete repeat measures of
the QUAL-EC questionnaire and the NCCN Distress
Thermometer. The researcher will interview the patient
using the family meeting patient semi-structured inter-
view schedule if a family meeting has been held. If the
patient participates in a family meeting after Day 7, the
researcher will undertake the interview at a convenient
time for the patient.
Day 14 repeat family measures
On Day 14 participating family member(s) follows the
same intervention site procedures concerning repeat
measures. If the family member(s) has attended a family
meeting, the family member will complete the Family
Meeting Family Feedback Questionnaire on-site or by
telephone. A sample of family members (n = 10) will
participate in an interview, using the QUAL-E (Family)
questions as per the intervention site procedures.
The researcher will consult regularly with clinicians to
promote participant retention and ensure complete
follow-up. Incomplete participant data and the reasons
for this will be documented. Pre- and post-measures that
are not completed when a participant withdraws from
the study will be excluded from the data analysis.
Data management
All patient and family participants in the VOICE Study
will be allocated a unique identification (ID) code that
will be entered on all questionnaires and linked with all
completed interviews. The relevant ID code will form
part of the data entry for the qualitative and quantitative
data. All data will be entered and stored on a secure
computer hard drive that will be backed up daily and be
firewall protected. All computers will be password pro-
tected. Only the researcher and her supervisor(s) will
have access to the master list that links participants to
the de-identified data and all data will be stored separ-
ately from the register of participants. All VOICE Study
documentation will be placed in a locked filing cabinet
in a locked office, in accordance with National Health
and Medical Research Council (NH&MRC), Australia
requirements [33].
Statistical methods
Quantitative measures and qualitative data collected for
the four study groups will be analysed.
Quantitative data
Prior to analysis of the quantitative date, all variables will
be assessed for accuracy of input, plausibility of means
and standard deviations and out-of-range and missing
values. The quantitative data will be analysed using Statis-
tical Package for the Social Sciences (SPSS). Descriptive
statistics (frequencies, means and medians) will be used to
summarise the baseline and follow-up data including
demographics, NCCN DT, PHQ-4, QUAL-EC and
QUAL-E (Family) measures and quantitative questions on
the feedback questionnaires. Differences on these variables
[NCCN DT, PHQ-4, QUAL-EC and QUAL-E (Family)]
between the intervention group and control group will be
assessed using univariate, parametric or non-parametric
statistics depending if these outcomes are normally or
non-normally distributed.
Qualitative data
All qualitative data will be reviewed prior to the com-
mencement of analysis. Patient interviews will be recorded
and transcribed verbatim. Data analysis will be conducted
using theoretical and procedural direction from grounded
theory research utilising the constant comparative method
[34]. The transcripts will be uploaded into the software
program QSR NVivo. Open, axial, and selective coding
will be used to analyse the data [35]. Iterative data analysis
will commence after the first interview with all investiga-
tors participating using the selected interview transcripts
and additional excerpts to identify and agree upon emer-
gent themes. The open-ended responses from the family
feedback questionnaires will be analysed using the
constant-comparative method. The clinician focus groups
will be recorded, transcribed verbatim, and analysed using
the constant comparative method. Sufficient numbers of
clinicians will participate in focus groups to ensure that
data saturation is achieved.
Additional analysis of the percentage of dyads re-
cruited, family meeting observations and feedback from
patients, families and clinicians will provide information
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about the feasibility of the meetings. The percentage of
completed questionnaires, patient and family feedback,
preferences and issues about the measures will provide
information about their feasibility and suitability from
the patient and family perspective.
Monitoring
A data monitoring committee will not be convened as
qualitative data will be reviewed and analysed iteratively
and involve all the investigators.
Harms
The Participant Information Statement and Consent
Form for patients and families will indicate that there is
small risk that completing the questionnaires and inter-
views may cause these participants to reflect on their life
and situation and become distressed. The form also
notes that sharing information about end-of-life issues
between patients and family members and hearing of
their concerns may also be distressing. The patients and
family will be advised that if they become upset or dis-
tressed as a result of participation in the VOICE Study,
the researcher will inform the treating doctor and the
clinical team. In the case of the patient, the clinical team
will arrange for counselling or other appropriate sup-
port. For family members, the clinical team will provide
information about support options available if that is
their wish.
Consent
The researcher or clinical trials nurses will obtain informed
consent from all participants in the VOICE Study. All par-
ticipants will be provided with the relevant Participant
Information Statement and Consent Form, according to
whether are participating at the intervention or control site
and will be required to read and understand the contents of
this document and provide their consent via a signature
before they are enrolled in the study.
Confidentiality
Where personal information about study participants is
collected, stored, accessed, used, or disposed of, the re-
searcher will ensure that the privacy and confidentiality of
the participants is maintained. Any information obtained
in connection with this study that could identify a partici-
pant will remain confidential. It will only be disclosed with
the participant’s permission. In any publication, informa-
tion will be provided in such a way that participants will
not be identified. All computerised data will be entered
and stored on a secure hard drive in a de-identified man-
ner, with password access for designated research staff
only. Only the researcher and her supervisors will have ac-
cess to this data.
Access to data
At the completion of the study, all data will be stored in
archive boxes, labelled and placed in a locked storage
room, which will be protected by a coded keypad. All
data and information associated with this research study
will be kept securely for 7 years according to NH&MRC
requirements [33]. The data collected will form part of a
formal handover by the researcher at the completion of
the study.
Dissemination policy
The results of the VOICE Study will be disseminated in ap-
propriate peer reviewed journals. A report will also be pro-
vided to participating family members who have requested a
summary of the research findings. Presentations of the
results to the participating sites will also be undertaken.
Discussion
Palliative care patients are generally seen as a vulnerable
group in terms of research because of their limited life
expectancy and the impost on them to participate in re-
search when they may be compromised physically and
psychosocially. Nevertheless, the currently limited high-
level evidence to support the routine use of family meet-
ings in the inpatient palliative care setting indicates that
this feasibility study is warranted. In particular, there is
limited evidence for patient and family benefits using
validated outcomes measures and limited qualitative evi-
dence to demonstrate advantages for clinicians.
This study will determine whether planned Patient-
Centred Family Meetings are feasible and acceptable to
participating patients, families and clinicians. It will also
assess the suitability and feasibility of the selected out-
come measures for patients and families. In addition, the
study is expected to enhance the understanding of the
benefits and burdens of participating in a planned
Patient-Centred Family Meetings for patients, families
and clinicians. The results will also inform the need for
a possible Phase III Randomised Controlled Trial.
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